Evercore ISI analyst Daniel Markowitz lowered the firm’s price target on Repligen (RGEN) to $140 from $170 and keeps an Outperform rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen: Strong Execution, Innovation, and Cross‑Selling Momentum Support Sustained Growth and Reaffirmed Buy Rating
- Repligen price target raised to $208 from $180 at H.C. Wainwright
- Repligen price target lowered to $195 from $200 at UBS
- Repligen price target lowered to $170 from $180 at Evercore ISI
- Repligen: Solid Execution and Credible Growth Outlook, But Upside Limited at Current Valuation